

# **Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2019**

<https://marketpublishers.com/r/I581FD6A750EN.html>

Date: November 2019

Pages: 151

Price: US\$ 2,000.00 (Single User License)

ID: I581FD6A750EN

## **Abstracts**

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2019

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2019, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 5, 10, 9, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecule, respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Companies Involved in Therapeutics Development

3SBio Inc

Amgen Inc

Argenx SE

Biotest AG

Clover Biopharmaceuticals

CSL Ltd

Enzene Biosciences Ltd

Genosco Inc

Genzyme Corp

HanAll Biopharma Co Ltd

Hutchison MediPharma Ltd

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Kezar Life Sciences Inc

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Pharmagenesis Inc

Pharmapraxis

Principia Biopharma Inc

Protalex Inc

Qilu Pharmaceutical Co Ltd

Rigel Pharmaceuticals Inc

Sichuan Kelun Pharmaceutical Co Ltd

Taiho Pharmaceutical Co Ltd

UCB SA

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles

batoclimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-595 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-730 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostamatinib disodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hetrombopag Olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-523 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
KLM-465 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
KZR-616 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
M-254 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
nipocalimab - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
PF-06755347 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
PHN-013 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
PRN-1008 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
PRTX-100 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
QL-0911 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

## Recombinant Protein to Agonize Thrombopoietin Receptor for Idiopathic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### romiplostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### romiplostim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### SCB-219 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### SKIO-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### sutimlimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### TAS-05567 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### thrombopoietin - Drug Profile

Product Description



Mechanism Of Action

R&D Progress

veltuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1: Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Universities/Institutes, H2 2019

Table 5: Products under Development by Companies, H2 2019

Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 8: Products under Development by Universities/Institutes, H2 2019

Table 9: Number of Products by Stage and Target, H2 2019

Table 10: Number of Products by Stage and Mechanism of Action, H2 2019

Table 11: Number of Products by Stage and Route of Administration, H2 2019

Table 12: Number of Products by Stage and Molecule Type, H2 2019

Table 13: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H2 2019

Table 14: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H2 2019

Table 15: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Argenx SE, H2 2019

Table 16: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Biotest AG, H2 2019

Table 17: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Clover Biopharmaceuticals, H2 2019

Table 18: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by CSL Ltd, H2 2019

Table 19: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Enzene Biosciences Ltd, H2 2019

Table 20: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, H2 2019

Table 21: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genzyme Corp, H2 2019

Table 22: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by HanAll Biopharma Co Ltd, H2 2019

Table 23: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Pipeline by Hutchison MediPharma Ltd, H2 2019

Table 24: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics Inc, H2 2019

Table 25: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd, H2 2019

Table 26: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Table 27: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Kezar Life Sciences Inc, H2 2019

Table 28: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals Inc, H2 2019

Table 29: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2019

Table 30: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, H2 2019

Table 31: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, H2 2019

Table 32: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmapraxis, H2 2019

Table 33: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Principia Biopharma Inc, H2 2019

Table 34: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex Inc, H2 2019

Table 35: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2019

Table 36: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, H2 2019

Table 37: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2019

Table 38: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019

Table 39: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by UCB SA, H2 2019

Table 40: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2019

Table 41: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2019 (Contd..1), H2 2019

Table 42: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Figure 1: Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products by Top 10 Targets, H2 2019

Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Molecule Types, H2 2019

Figure 10: Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

3SBio Inc

Amgen Inc

Argenx SE

Biotest AG

Clover Biopharmaceuticals

CSL Ltd

Enzene Biosciences Ltd

Genosco Inc

Genzyme Corp

HanAll Biopharma Co Ltd

Hutchison MediPharma Ltd

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Kezar Life Sciences Inc

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Pharmagenesis Inc

Pharmapraxix

Principia Biopharma Inc

Protalex Inc  
Qilu Pharmaceutical Co Ltd  
Rigel Pharmaceuticals Inc  
Sichuan Kelun Pharmaceutical Co Ltd  
Taiho Pharmaceutical Co Ltd  
UCB SA

## I would like to order

Product name: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/I581FD6A750EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I581FD6A750EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

